Soriot Effect Sees AstraZeneca Selectively Scale Back Branded Generics In Emerging Markets
This article was originally published in PharmAsia News
Executive Summary
Leadership change is forcing the Anglo-Swedish drug giant to review its priorities in the branded generics business. AstraZeneca will invest selectively in countries where it has built a high base and shows ability to post robust growth.